Trial reportZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial].
Trial report in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). Although intrathecal Pemetrexed chemotherapy can effectively prolong patient survival, a high incidence of neurotoxicity has emerged as a critical factor limiting its clinical application. This study aims to investigate the efficacy and safety of Huangqi Guizhi Wuwu decoction (HGWD) in mitigating neurotoxicity induced by intrathecal Pemetrexed chemotherapy in NSCLC patients with LM.
methodsIn a prospective, randomized, double-blind, controlled trial, 220 NSCLC patients with LM were enrolled and randomly assigned to either the treatment group (HGWD+intrathecal chemotherapy) or the control group (placebo+intrathecal chemotherapy), with 110 patients in each group. The incidence and grade of neurotoxicity, disease control rate (DCR), progression-free survival (PFS), overall survival (OS), quality of life, and adverse reactions were observed and compared between the two groups.
resultsThe incidence of neurotoxicity in the treatment group was 29.1%, significantly lower than that in the control group (51.8%)(P<0.001). The incidences of both grade 1-2 and grade 3-4 neurotoxicity were lower in the treatment group than in the control group (P<0.010). Nerve conduction studies showed that the sensory nerve action potential amplitude of the sural nerve was significantly higher in the treatment group than in the control group (P=0.012), and the conduction velocities of the median and ulnar nerves showed a trend toward improvement. The DCR was 76.4% in the treatment group, higher than 69.1% in the control group (P=0.045). Both median PFS (7.8 vs 6.1 mon, P<0.001) and median OS (10.5 vs 8.9 mon, P=0.007) were significantly prolonged in the treatment group. Improvements in quality of life and traditional Chinese medicine syndrome scores were superior in the treatment group (P<0.05). No significant difference in adverse reactions were observed.
conclusionsHGWD can significantly reduce the incidence of neurotoxicity induced by Pemetrexed intrathecal chemotherapy, improve chemotherapy tolerance and survival benefits, with a good safety profile in NSCLC patients with LM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.